Stockreport

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Inc.  (ALMS) 
PDF – Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with [Read more]